The abstract is read at the publisher; the summary is JClub's.
ERBB2 activating mutations in HER2-non-amplified metastatic breast cancer are linked to longer trastuzumab deruxtecan rwPFS, with 11 versus 6.2 months versus wild-type.
- Why it matters: It is unclear whether ERBB2 activation can strengthen T-DXd benefit in metastatic breast cancer lacking HER2 amplification, including cases with very low HER2 staining.
- What they did: In 272 T-DXd–treated patients with somatic sequencing, rwPFS was estimated by Kaplan-Meier and tested with Cox models; ERBB2 mutants were also modeled in breast cell lines to measure T-DXd internalization kinetics and IC50.
- The result: ERBB2 mutations remained independently associated with longer rwPFS after adjustment (HR 0.49, 95%CI 0.25–0.96, p=0.038), and in CAMA-1, T47D, and MCF10A cells mutants showed faster internalization and lower IC50 (0.017–0.070 vs 2.86 µg/mL).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.